Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on August 11, 2026.

What the trial team says

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number: NCT07486713
Stage of testing: Phase 4
Conditions studied: AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies

Where it is running

This trial lists 2 sites.

California
- UCI Irvine Health (Orange)
New York
- New York Presbyterian Hospital-Columbia University Medical Center (New York)

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.